Small Molecule Targeted Cancer Therapy Market

The global small molecule targeted cancer therapy market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to its huge adoption rate and minimum adverse effects of the therapy.

Get Free Sample Report

The small molecule targeted cancer therapy is a rapidly growing and widely adopted treatment process for targeted cancer patients. In general, patients tend to use several alternative drugs available in the market to treat the disease. However, rising patent expiry of the drugs such as Glivec of Novartis, is an immense opportunity for manufacturers to develop new targeted drugs, which act to prevent cancerous cell growth. Therapies such as conventional medications and chemotherapy are likely to destroy the cells and stop the cell growth rapidly. The small molecule targeted therapy destroy cancer cells with better efficiency and less side effects. There are various types of cancers such as prostate cancer, multiple myeloma, lymphoma, melanoma and breast cancer which are treated by this targeted therapy.

To increase the compliance and self-care ability to the patients who went through small molecule therapy, the International Society of Nurse in Cancer Care initiated Led Small Molecule Chemotherapy Patient Education Program, which is funded by Glaxo Smith Kline. Small molecules target the intra-cellular protein and spike the aperture of a tumor. Identification and purity of small molecule target cancer cells is certified due to purification, chemical synthesis, and molecular characterization techniques to make them effortless to reproduce. Antibodies are regulated intravenously, while small molecules can be orally regulated. Small molecules therapy if proven successful is expected to be another treatment for the cancer immunotherapy.

Market Trends, Drivers, Restraints, and Opportunities

• High prevalence rates of cancer and wide demand for advanced therapy method for cancer treatment are expected to boost the market growth.
• Wide availability of drugs and medications for the treatment of the disease is projected to propel the market expansion.  
• Massive R&D activities by major healthcare players and major competitive of global players are estimated to expand the market growth.
• High cost of the treatment acts as a major challenge that can hamper the market expansion during the forecast period. 
• Wide awareness of the treatment drugs and inclination of the targeted people regarding cancer diagnosis are anticipated to push the market growth.

Scope of the Report                         

The report on the global small molecule targeted cancer therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Monoclonal antibodies segment is expected to grow at a rapid pace

Based on applications, the global small molecule targeted cancer therapy market is segregated into small molecules, monoclonal antibodies, and small molecule drug conjugates. The small molecules is further divided into small molecule cyclin-dependent kinase inhibitor, small molecule tyrosine kinase inhibitor, and small molecule proteasome inhibitor. The monoclonal antibodies is sub-classified as fully human antibody, chimeric monoclonal antibody, humanized monoclonal antibody, and humanized monoclonal antibody. The monoclonal antibodies segment is expected to grow at a rapid pace during the forecast period due to its huge adoption rates for the disease treatment. On the other hand, the small molecules segment is estimated to expand at a substantial growth rate during the forecast period owing to high precision and few side effects.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a key share of the market in 2020 and is projected to exhibit a high CAGR during the forecast period owing to increasing incidences of cancer in the region. The market of Asia Pacific, however, is estimated to grow at a rapid pace during the forecast period due to growing infrastructure and various initiatives for awareness in people and for R&D activities in the region.

Get Free Sample Report

Segments

The global small molecule targeted cancer therapy market has been segmented on the basis of

Applications

• Small Molecules
  • Small Molecule Cyclin-dependent Kinase Inhibitor
  • Small Molecule Tyrosine Kinase Inhibitor
  • Small Molecule Proteasome Inhibitor
• Monoclonal Antibodies
  • Fully Human Antibody
  • Chimeric Monoclonal Antibody
  • Humanized Monoclonal Antibody
  • Humanized Monoclonal Antibody
• Small Molecule Drug Conjugates

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Bayer HealthCare AG
• Cytokinetics Inc.
• Hospira Inc.
• OncoGenex Pharmaceuticals Inc.
• GlaxoSmithKline PLC

Competitive Landscape

Key players competing in the global small molecule targeted cancer therapy market are Abbott Laboratories; Boehringer Ingelheim GmbH; Bayer HealthCare AG; Cytokinetics Inc.; Hospira Inc.; OncoGenex Pharmaceuticals Inc.; and GlaxoSmithKline PLC. The main market players are continuously engaged in various development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations to enhance their market position globally. BeiGene got its cancer drugs in clinic tests, listing poly ADP ribose polymerase inhibitor and a la ibrutinib, BRAF inhibitor.